Hori­zon snaps up rare dis­ease drugs, pipeline, in $800M Rap­tor buy­out

Hori­zon Phar­ma has bagged Rap­tor Phar­ma­ceu­ti­cals $RPTP and a pair of rare dis­ease drugs on the mar­ket — along with a mul­ti-drug pipeline — in an $800 mil­lion cash deal. Hori­zon is pay­ing $9 a share for Rap­tor, which al­so has been pur­su­ing a trou­bled de­vel­op­ment path for a new drug for Hunt­ing­ton’s drug, now in a piv­otal tri­al.

Hori­zon $HZNP is look­ing for some quick re­turns on Rap­tor’s two ap­proved drugs, Pro­cys­bi and Quin­sair, used to treat a rare meta­bol­ic dis­or­der called nephro­path­ic cysti­nosis and chron­ic pul­monary in­fec­tions due to Pseudomonas aerug­i­nosa in adult pa­tients with cys­tic fi­bro­sis. Pro­cys­bi has U.S. and Eu­ro­pean ap­provals, while Quin­sair is OK’s in Eu­rope and Cana­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER